Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
60Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $24.05M | $-243.32M | $-2.32 |
| 2024 | $0.00 | $-294.23M | $-10.38 |
| 2023 | $0.00 | $-154.99M | $-2.99 |
| 2022 | $0.00 | $-111.93M | $-14.93 |
Social Signal Score
Earnings
Thu, Nov 12(in 3 months)
Consensus estimate $-0.72 per share
Typical surprise -5.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-1.11 vs $-0.77miss
- Thu, May 14$-0.74 vs $-0.74beat
- Thu, Mar 19$-0.95 vs $-0.97beat
- Thu, Nov 13$-1.06 vs $-0.92miss
- Wed, Aug 13$-1.17 vs $-1.11miss
- Wed, May 14$-1.82 vs $-1.47miss
Estimates and results for ALMS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
ALMShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newszacks.com·4d ago·Negative
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026 PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
View source ↗